Amicus Therapeutics Inc (FOLD)

5.96
NASDAQ : Health Care
Prev Close 6.05
Day Low/High 5.87 / 6.03
52 Wk Low/High 4.41 / 9.83
Avg Volume 3.71M
Exchange NASDAQ
Shares Outstanding 142.69M
Market Cap 863.29M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Short Interest In Amicus Therapeutics Jumps 14%

Short Interest In Amicus Therapeutics Jumps 14%

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 4,046,337 share increase in total short interest for Amicus Therapeutics Inc , to 32,785,226, an increase of 14.08% since 01/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Interesting FOLD Call Options For February 17th

Interesting FOLD Call Options For February 17th

Investors in Amicus Therapeutics Inc saw new options become available this week, for the February 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FOLD options chain for the new February 17th contracts and identified the following call contract of particular interest.

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo

Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo

Amicus Therapeutics, Nantkwest and Organovo are among the premarket biotech movers on Tuesday.

October 20th Options Now Available For Amicus Therapeutics (FOLD)

October 20th Options Now Available For Amicus Therapeutics (FOLD)

Investors in Amicus Therapeutics Inc saw new options become available today, for the October 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 276 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies -- including Occidental Petroleum and Six Flags Entertainment -- have been scooping up shares of their own stock lately.

3 Small Biotechs With Insider Buying

3 Small Biotechs With Insider Buying

Insiders have an edge in this complex sector, so it's worth checking them out.

A Biotech Trio to Like Going Into 2017

A Biotech Trio to Like Going Into 2017

Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.

FOLD Makes Notable Cross Below Critical Moving Average

FOLD Makes Notable Cross Below Critical Moving Average

In trading on Tuesday, shares of Amicus Therapeutics Inc crossed below their 200 day moving average of $7.13, changing hands as low as $6.30 per share. Amicus Therapeutics Inc shares are currently trading off about 22.2% on the day.

Futures Flat as Investors Take Profits; Asia Mixed

Futures Flat as Investors Take Profits; Asia Mixed

Futures remain soft, but analysts believe rally still has steam.

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.

4 Promising Small Biotechs to Watch in 2017

4 Promising Small Biotechs to Watch in 2017

Veterinary drug play Aratana Therapeutics is among the potential solid performers next year.

TheStreet Quant Rating: D- (Sell)